Noxopharm Pty Ltd

NGG is advising NOX on commercialising and licensing their IP to deliver specialised onco-care in India

Overview

Noxopharm is an Australian publicly-listed (ASX:NOX) clinical stage drug development company. The clinical stage drug candidate is Veyonda® (previously known as NOX-66). Veyonda® is a first-in-class, dual-acting cytotoxic and immuno-oncology drug candidate designed to enhance the effectiveness and safety of both chemotherapy and radiotherapy. At one level, Veyonda® enhances the cancer-killing effect of standard chemotherapy and radiotherapy, thereby enabling lower doses of these toxic therapies to be used. At another level, it seeks to activate the body’s innate immune cell function to attack those cancer cells that have survived the initial treatment. Veyonda® appears to work across the broad spectrum of cancers. The ultimate aim is to harness the body’s immune system to inflict damage on ALL cancer cells in the body, eradicating most, if not all cancer cells to produce long-term remission or even a curative outcome in what is known as an abscopal effect. An abscopal effect is where radiotherapy is applied to just the one lesion, and triggers a response in all other non-irradiated lesions.

NGG was engaged by NOX to assist it entry into India. NGG prepared a detailed report NOX, which shared New India’s growth opportunities in the health sector, and provided market insights on India’s Cancer Care, specifically focusing on Prostate Cancer, and opportunities to build strategic partnerships with public and private organisations.

NGG is supporting NOX’s India goals and in helping it to explore, enter, and expand in the Indian market, focusing on commercializing and licensing its expertise and IP, and setting an example towards strong Australia India Bio-Tech/Health Sector engagement.

Operational Summary

The Company previously operated a health food wholesale supply and catering business under the 'About Life' brand. An opportunity exists for a purchaser to take advantage of an extensive fit-out and make use of the Company's commercial kitchen equipment, food preparation and storage/warehousing facilities. The landlord of the Company's premises has also agreed to negotiate a new lease for the prospective purchaser.

Key features of the sale include:

  • Fit-out at leased premises (7,755m2) including several cool / freezer rooms, IT & office equipment, warehouse pallet racking.

  • Commercial kitchen appliances for food preparation, cooking and packaging including ovens, washing equipment, packaging machines.

  • Ancilliary equipment including commercial cookware, materials handling, food storage, cooler room racking etc.

For further information regarding the business which the Company operated, please visit:

https://www.xyz.com.au/

Financial & Strategic Overview

Revenue:

  • 2020FY (projected): $30m

  • 2019FY: $27m

EBITDA:

  • 2020FY (projected): $5-5.5m

  • 2019FY: $5m

  • 2018FY: $5m

Asking price (including two freehold commercial properties): $14m + stock at value (approx. $3m)

COVID-19 will have minimal impact on the business & may result in increased demand as clients are holding higher stock levels with some requiring additional storage (supplied by this business).

Sales have grown consistently and the sales outlook is positive as Australian businesses renew emphasis on domestically manufactured products. Infrastructure & capital intensive projects are being brought forward as a result of Federal and State fiscal policy - another factor likely to grow demand.